Table 1.

Patient demographics and baseline CSF measures

Demographic	EXPEDITION + EXPEDITION2		EXPEDITION3
	Solanezumab	Placebo	Solanezumab	Placebo
	CSF sample (n = 120)	CSF sample (n = 121)	CSF sample (n = 211)	CSF sample (n = 210)
Age, years	71.7 (8.6)	72.1 (7.45)	71.4 (7.89)	71.9 (7.55)
Female, N (%)	59 (49.2)	67 (55.4)	122 (57.8)	115 (54.8)
CSF total Aβ1–40, pg/mL	10,700 (3460)	10,800 (4000)	11,100 (4970)	10,700 (4320)
CSF total Aβ1–42, pg/mL	741 (339)	698 (326)	737 (220)	747 (226)
CSF free Aβ1–40, pg/mL	6110 (1810)	6310 (2030)	5700 (2030)	5750 (2030)
CSF free Aβ1–42, pg/mL	300 (184)	289 (158)	272 (99.3)	278 (103)

Abbreviations: Aβ, amyloid β; CSF, cerebrospinal fluid; N, number of patients; n, number of samples; SD, standard deviation.

NOTE. Patient demographics and baseline CSF are for patients with CSF measures. Unless otherwise noted, demographic data are shown as mean (SD).